Nestlé Health Science to acquire VOWST assets from Seres Therapeutics
Seres Therapeutics, Inc. (Nasdaq: MCRB) has announced a significant development in its partnership with Nestlé Health Science—a non-binding memorandum of understanding whereby Nestlé Health Science ... Read More
Seres Therapeutics gets FDA priority review designation for SER-109 in rCDI
Seres Therapeutics has secured priority review designation from the US Food and Drug Administration (FDA) for SER-109, its investigational oral microbiome therapeutic for the prevention ... Read More
Seres Therapeutics begins Phase 1b trial for SER-301 in active ulcerative colitis
Seres Therapeutics, a prominent US-based biotech company, has announced the commencement of dosing in a Phase 1b clinical trial for SER-301, a novel microbiome-based therapeutic ... Read More